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SUMMARY
Background
In primary biliary cirrhosis (PBC), biochemical criteria at 1 year are considered
surrogates of response to ursodeoxycholic acid (UDCA). However, due to the
slow natural history of PBC, evaluation at 1 year may be suboptimal to assess
the therapeutic response, particularly in early disease.
Aim
To determine whether evaluation of biochemical criteria at 1 year is a reliable
surrogate of UDCA response in early PBC.
Methods
We analysed the prospectively collected data of 215 patients (untreated = 129;
UDCA-treated = 86) with early PBC (normal baseline bilirubin/albumin) and a
median follow-up of 8 years (range: 1–29.1). The 1-year attainment rates of the
Barcelona, Paris-I, Paris-II and Toronto deﬁnitions, and their predictive rele-
vance for a poor outcome (death, transplantation, complications of cirrhosis),
were assessed either as a result of UDCA or no treatment. Independent associ-
ations with attaining each UDCA response deﬁnition were identiﬁed by
multivariate analysis.
Results
Untreated patients displayed 1-year biochemical features compatible with ‘treat-
ment response’ at rates (Barcelona: 36.4%, Paris-I: 66.7%, Toronto: 59.7%,
Paris-II: 40.3%) similar to those obtained under UDCA. Depending on the def-
inition, baseline ALP≤3xULN (OR: 4.80–35.90), AST≤2xULN (OR: 5.63–9.34)
and early histological stage (OR: 3.67–3.87) were the stronger predictors for
attaining the criteria. UDCA treatment was associated with attaining Barcelona
(OR = 2.16) and Paris-II (OR = 2.84), but not Paris-I, and not Toronto deﬁni-
tion when excluding late histological cases. Paris-I criteria were signiﬁcantly
predictive of long-term outcomes (HR = 2.83) in untreated patients.
Conclusions
In early PBC, biochemical criteria at 1 year reﬂect severity of the disease rather
than the therapeutic response to UDCA.
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INTRODUCTION
Primary biliary cirrhosis (PBC) results from progressive
immune-mediated destruction of small and medium size
intrahepatic bile ducts, which may lead to cirrhosis, liver
failure and requirement for liver transplantation (LT).1
Currently, ursodeoxycholic acid (UDCA) is the only
approved therapy in PBC,2–5 which improves liver bio-
chemistry,6, 7 and may delay histological progression,8, 9
although an overall survival beneﬁt is disputed.10, 11
Nonetheless, the patients’ transplant-free survival with
UDCA remains lower than in age- and sex-matched con-
trols from the general population; thus, new therapeutic
approaches are needed.12 As the natural history of PBC
is slow, deﬁnition of surrogate markers of disease pro-
gression is of cardinal importance for both clinical prac-
tice and design of clinical trials.13 Recently, a number of
cohort studies have shown a correlation between the
magnitude of biochemical response to UDCA and long-
term outcomes, including transplantation-free survival14–16
and histological progression.17 Thus, biochemical
responses evaluated after 1 or 2 years of UDCA therapy
have become surrogate markers of therapeutic efﬁcacy in
PBC. However, a point for criticism may be that no study
proposing an UDCA biochemical response has so far
included untreated patients with PBC.14–18 Indeed, the
development of UDCA response criteria relied on sepa-
rating ‘responders’ to UDCA with favourable clinical out-
comes from ‘nonresponders’, compared with age- and
sex-matched healthy controls, but had no comparison
with matched untreated PBC patients. Due to the lack of
this measure, the strength of the causal association
between biochemical responses and the actions of UDCA
might have been not thoroughly assessed. Notably, in a
recent abstract, the most validated UDCA response crite-
ria, Paris-I (PA-I), were shown to maintain excellent
prognostic ability irrespective of UDCA therapy, ques-
tioning their ability to reﬂect a drug effect.19 Currently,
most PBC patients are diagnosed early during their dis-
ease course, when bilirubin is normal (and thus impossi-
ble to be evaluated prognostically), whereas alkaline
phosphatase (ALP) and aspartate transaminase (AST)
may be minimally elevated. Thus, early evaluation of
these variables with respect to assessing a therapeutic
response may be problematic. Not surprisingly, the most
validated biochemical response criteria [Barcelona (BA)
and PA-I] do not predict outcomes with UDCA in early
PBC,16, 18 whereas the Rotterdam criteria16 have little
applicability because they require abnormal baseline bili-
rubin and albumin values. Newer criteria [Paris-II
(PA-II)] are now proposed as best in early PBC,18 but
still lack external validation. Focusing on early PBC, the
present study aimed to investigate the strength of the
causal association between treatment with UDCA and
four published biochemical response criteria evaluated at
1 year. Using a cohort of untreated early PBC patients
with prolonged follow-up, we determined to which extent
1-year UDCA response deﬁnitions may occur, and be
predictive of poor prognosis, in patients receiving no
treatment. Magnitude of this effect was compared with
that obtained under UDCA in our institution and pub-
lished series. Furthermore, we identiﬁed independent
associations with attaining each biochemical deﬁnition,
including 1-year treatment with UDCA as a candidate
variable.
METHODS
Patients
In a prospectively collected database of consecutive
patients with PBC referred between 1977 and 2001, used
in earlier publications,20–23 we evaluated those with non-
histological deﬁnition of early disease, i.e. normal base-
line bilirubin and albumin levels.12 The diagnosis of PBC
was made with positive anti-mitochondrial antibodies
(AMA) and ALP> 1.5x the upper normal limit (ULN),
and/or by liver histology compatible with PBC. Overall,
there were 81 (37.7%) patients with baseline ALP ≤1.5x
ULN (all AMA-positive), whereas another 25 (11.6%)
were AMA-negative. In both these subsets of patients,
the diagnosis of PBC was established histologically. Liver
biopsies were evaluated if performed within 12 months
of database entry and staged using Scheuer’s classiﬁca-
tion.24 All patients had follow-up data including UDCA
biochemical response parameters (serum bilirubin, ALP
and AST concentrations), before and after 1 year from
presentation and/or diagnosis, and/or UDCA starting
date. Data-points were 3- to 6-monthly routine clinical
visits, or whenever attending or admitted to hospital.
The date of diagnosis, presentation to Royal Free Hospi-
tal, UDCA starting date, date of complications, date of
last follow-up, date of LT or death and causes of death
were recorded. Nontreatment with UDCA was either
because patients were diagnosed and followed up in the
pre-UDCA era, or because this was the choice made fol-
lowing consultation between the patient and the treating
physician, who was a hepatologist in all cases. We analy-
sed untreated patients from when ﬁrst seen at the Royal
Free Hospital, and treated patients from ﬁrst date of
UDCA administration. Autoimmune overlap syndrome25
or other concomitant liver disease, immunosuppressive
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drug use and follow-up <1 year were exclusion criteria.
As late histology adversely impacts both UDCA response
and long-term prognosis, we planned a subanalysis,
excluding patients with Scheuer’s stages III/IV at
baseline.
Deﬁnition of biochemical and clinical endpoints
Biochemical features in untreated and treated PBC
patients were evaluated 1 year after study entry, with
regard to fulﬁlling four published UDCA response deﬁni-
tions (Table 1). Each biochemical deﬁnition, irrespective
of attended or not as a result of UDCA, was evaluated as a
prognostic surrogate for an adverse outcome, deﬁned as
whichever occurred ﬁrst of complications of cirrhosis
(ascites, variceal bleeding, hepatic encephalopathy or
hepatocellular carcinoma), liver-related death (liver failure
and/or complications above) or LT. Follow-up was cen-
sored at death or LT or at ﬁrst occurrence of complication,
or at last follow-up. The Toronto criteria17 were based on
2 years of UDCA therapy, using a histological endpoint:
ALP ≤1.67x ULN with a one-stage increase or ALP ≤1.76x
ULN with a two-stage increase. To make our results com-
parable to a recent study in early PBC,18 we used the ALP
<1.76x ULN TO criteria with a clinical endpoint. We did
not evaluate the Rotterdam deﬁnition,16 as it was not
applicable to our patients with normal baseline bilirubin
and albumin.
Statistical analysis
The baseline demographic and clinical characteristics are
presented as percentage, or means with standard
deviations (s.d.), or median (range); comparisons were
performed with v2 or Fisher’s exact tests for categorical
data and Student’s t or Mann–Whitney U tests for con-
tinuous data, as appropriate. Comparisons of biochemi-
cal values before and after 1 year were performed using
the Wilcoxon signed-rank test. Using the whole cohort
(n = 215), univariate analysis was evaluated to identify
associations with attaining 1-year response criteria
deﬁned by BA, PA-I, TO and PA-II criteria. Variables
achieved signiﬁcance (P < 0.1) in univariate analysis,
entered into multivariate logistic regression, except for
UDCA therapy, which was kept independent of its uni-
variate signiﬁcance. Long-term outcomes were estimated
with Cox proportional-hazards regression models using
the average hazard ratio (HR) with 95% conﬁdence
intervals (CI). Time-to-event analysis was evaluated by
Kaplan–Meier method and comparisons were evaluated
using log-rank testing. The statistical analyses were per-
formed using SPSS statistics version 19 (IBM, Armonk,
NY, USA). All analyses were two-sided and P-values
<0.05 were considered statistically signiﬁcant.
RESULTS
Descriptive data
From the 498 consecutive patients with PBC, 228 ful-
ﬁlled nonhistological deﬁnition of early disease. Thirteen
patients were excluded: 11 had incomplete biochemical
data, and in 2, follow-up was <1 year. Therefore, 215
patients (untreated = 129; UDCA-treated = 86, 96.3%
females, age: 56.8  11.8 years) ﬁnally comprised the
study population (Table S1). In those receiving UDCA,
the mean dosage was 15 mg/kg/day (s.d. = 5; range 7–
23 mg/kg/day): 34 received low-dose UDCA and 52
received high-/standard-dose UDCA (mean 17 mg/kg/
day; range 13–23). No signiﬁcant baseline clinical or
biochemical differences were detected between stan-
dard-/high-dose and low-dose UDCA groups (data not
shown). The untreated and UDCA-treated groups had
similar demographic, clinical and biochemical character-
istics (Table 2), except for median baseline bilirubin
(untreated: 9; 3–16 lmol/L, UDCA-treated: 10; 5–
17 lmol/L, P = 0.04). In patients with liver biopsy
(untreated: 85; 65.9%, UDCA-treated: 77; 89.5%), late
histological stages (Scheuer’s stages III/IV) were found
in 25.9% untreated vs. 10.4% UDCA-treated patients
(P = 0.01). Mean time between diagnosis and presenta-
tion to Royal Free Hospital was 1.7  2.1 years,
whereas between diagnosis and starting of UDCA was
2.1  3.5 years (P = 0.060), obviating lead-time bias in
Table 1 | Published criteria of biochemical response to
ursodeoxycholic acid in patients with primary biliary
cirrhosis
Criterion
Deﬁnition of
biochemical response
Barcelona15 ALP decrease >40% from baseline or to normal
after 1 year of UDCA.
Paris-I14 ALP ≤3x ULN, AST ≤2x ULN and normal bilirubin
after 1 year of UDCA.
Toronto17 ALP ≤1.67x ULN* or ALP ≤1.76† after 2 years of
UDCA.
Paris-II18 ALP and AST ≤1.5x ULN with normal bilirubin
after 1 year of UDCA.
ALP, alkaline phosphatase; UDCA, ursodeoxycholic acid; AST,
aspartate transaminase; ULN, upper limit of normal.
Toronto criteria were developed using a histological endpoint:
* Deﬁning nonresponse as a one-stage increase.
† Deﬁning nonresponse as a two-stage increase.
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the nontreated group. All patients had complete bio-
chemical data regarding baseline and 1-year serum bili-
rubin, ALP and AST serum values, whereas serum
albumin concentrations at 1 year were available in 170
(79.1%) patients (UDCA: 79; 41.6%, non-UDCA: 91;
53.5%). After 1 year of UDCA, ALP and AST decreased
signiﬁcantly (P = 0.0001 for both; Table 3a), whereas all
but one patient (which decreased albumin to 34 g/L)
maintained normal bilirubin and albumin concentra-
tions. In untreated patients, median bilirubin
concentration increased (P = 0.001), whereas ALP, AST
and albumin remained largely unchanged (P = 0.15,
0.90 and 0.15 respectively; Table 3a). Overall, 14/129
(10.8%) untreated patients did not maintain nonhisto-
logical deﬁnition of early disease at 1 year: bilirubin
increased above ULN in 13 patients, and 1 patient
showed increased bilirubin and reduced albumin; all 13
had either stage III (4) or stage IV (5), except 4 with-
out biopsy. When excluding patients with known Sche-
uer’s III/IV stage (as not balanced between untreated
and UDCA groups), there was also a reduction in ALP
concentration in untreated patients (P = 0.05, Table 3b).
Adverse outcomes occurred in 34 (15.8%); 26
untreated/8 UDCA (P = 0.04): liver-related death 9
(4.2%): 8 untreated/1 UDCA (P = 0.09); complications
18 (8.4%): 12 untreated (ascites 6, variceal bleeding 4,
encephalopathy 1, HCC 1)/6 UDCA (ascites 4, variceal
bleeding 2) (P = 0.62); and liver transplantation 7
(3.3%): 5 untreated/2 UDCA (P = 0.70). The survival
rates without adverse outcome at 5, 10, 15 and 20 years
were 92.2%/80.1%/74.9%/59.3%, respectively, for
untreated patients, vs. 93.6% at 5 and 10 years and
87.4% at 15 and 20 years for UDCA-treated group
(P = 0.11). Excluding late histological stages, an adverse
outcome was documented for 20/185 (10.8%): 15
untreated/5 UDCA (P = 0.15), comprising a ﬁrst com-
plication in 14:10 untreated/4 UDCA (P = 0.40), liver
transplantation in 4:3 untreated/1 UDCA(P=0.64) and
liver-related death in 2 (both untreated, P = 0.51). Sur-
vival rates free of an adverse event at 5, 10, 15 and
20 years were 95.8%/84.9%/78% and 56.7%, respectively,
if untreated, vs. 98.7% at 5 years, and 93.8% at 10, 15
and 20 years with UDCA (P = 0.03).
One-year biochemical features according to BA, PA-I,
TO and PA-II deﬁnitions and correlated factors
Comparative attainments of 1-year biochemical deﬁni-
tions, between untreated and UDCA patients, are
shown in Figure 1. Biochemical response to UDCA ran-
ged from 51.2% to 76.7%, whereas 36.4–66.7% of
untreated patients spontaneously fulﬁlled response deﬁ-
nitions. Signiﬁcant differences between UDCA and
untreated groups were found for attaining BA
(P = 0.03) and TO (P = 0.04) criteria (Figure 1a). How-
ever, there were no statistically signiﬁcant differences
between the two groups when excluding patients with
known late baseline histology (Figure 1b), or consider-
ing those with less prominent baseline biochemical
abnormalities: ALP ≤3x ULN (Figure 1c) or AST ≤2x
ULN (Figure 1d).
Table 2 | Comparison of baseline characteristics
between patients with early primary biliary cirrhosis
(normal baseline bilirubin and albumin) receiving no
treatment and those treated with ursodeoxycholic acid
Untreated
(n = 129)
UDCA-treated
(n = 86)
Age 56.8 (11.4) 56.9 (12.4)
Female gender 125 (96.9) 82 (95.3)
Total bilirubin (lmol/L) 9 (3–16)* 10 (5–17)*
ALP (U/L) 240 (50–1730) 226.5 (42–1074)
AST (U/L) 44.5 (18–312) 58 (14–270)
Albumin (g/L) 42 (35–51) 42 (35–57)
Prothrombin time (s) 12.9 (0.9) 12.1 (1.9)
INR 0.95 (0.1) 0.99 (0.07)
AMA-positive 117 (90.7) 73 (84.9)
IgM (g/L) 3.7 (3.2) 4.1 (3.6)
IgG (g/L) 15.5 (11.5) 15.4 (6.5)
Histology staging (n=162)
n = 85 n = 77
I 51 (60) 33 (42.9)
II 12 (14.1) 36 (46.8)
III 15 (17.6) 5 (6.5)
IV 7 (8.2) 3 (3.9)
Late (III, IV) 22 (25.9)** 8 (10.4)**
Risk scores†
Mayo risk score27 3.99 (0.63) 3.99 (0.71)
Royal Free score20 4.73 (0.82) 4.53(0.91)
ALP, alkaline phosphatase; AST, aspartate transaminase; INR,
international normalised ratio; AMA, anti-mitochondrial anti-
body; IgM, immunoglobulin M; IgG, immunoglobulin G. Quali-
tative variables are reported as n(%); quantitative variables as
mean (standard deviation), except for bilirubin, ALP and AST
and albumin reported as median (range). Statistically signiﬁ-
cant differences between the untreated and UDCA-treated
cohorts are indicated by asterisks: *P = 0.04, **P=0.01.
† Risk scores were calculated as follows: Mayo Risk Score,
R = 0.871 9 loge (bilirubin [mg/dL])  2.53 9 loge (albumin
[g/dL]) + 0.039 9 age (years) + 2.38 9 loge (prothrombin
time[s]) + 0.859 9 oedema (0 = no oedema, no diuretic ther-
apy; 0.5 = oedema, no diuretic therapy or no oedema, diuretic
therapy; 1 = oedema and diuretic therapy); Royal Free Score,
R = [0.55 9 age (years) + 21 9 log10 (bilirubin [lmol/L]) – 1
9 (albumin [g/L]) + 8 9 ascites (0 = no ascites; 1 = presence
of ascites)  55]/10.
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Univariate and multivariate analysis. Univariate and
multivariate associations for the attainment of each bio-
chemical response deﬁnition are shown in Table 4.
Depending on the deﬁnition, baseline ALP ≤3x ULN, AST
≤2x ULN and early histology (Scheuer’s I/II) remained
independently associated with attainment of biochemical
criteria. Receiving UDCA was independently associated
with attaining BA (P = 0.03), TO (P = 0.01) and PA-II
(P = 0.02), but not PA-I criteria (P = 0.24). Excluding
baseline Scheuer’s III–IV stages, both PA-I (P = 0.29) and
TO response criteria (P=0.08) occurred irrespective of
receiving UDCA (Table 4b). Dosage of UDCA was not
signiﬁcantly associated with attaining biochemical criteria,
even after excluding late-stage cases (Table 4a,b).
BA, PA-I, TO and PA-II as predictors of long-term
outcomes in early PBC
Curves for survival without an adverse outcome showed
a nonstatistically signiﬁcant trend for better 5-, 10- and
15-year outcomes in responders vs. nonresponders to
UDCA (Figure 2a); BA: 94.9% at all time-points vs.
92.3%/82%/82%; (P = 0.21), PA-I: 100%/92.4%/92.4%
vs. 100%/100%/70%; (P = 0.42), TO: 95.7%/89.3%/89.3%
vs. 92.6%/82.6%/82.6%; (P = 0.74) and PA-II: 100%/
96%/96% vs. 100%/92.7%/79.6% respectively (P = 0.28).
Excluding late baseline histology gave similar results:
P = 0.09 for BA, 0.74 for PA-I, 0.11 for PA-II and 0.20
for TO criteria (data not shown).In untreated patients,
failure to attain PA-I criteria at 1 year was signiﬁcantly
associated with poor outcome (HR: 2.83, 95% CI: 1.24–
6.45, P = 0.01) (Figure 2b), whereas no criterion was
predictive after excluding late-staged cases. Cox regres-
sion analysis in the evaluation of an adverse outcome
included all variables in Table 4a and in addition: pruri-
tus at baseline, AMA positivity and variables at 1 year
(bilirubin > ULN, absence of BA/PA-I/PA-II/TO crite-
ria). Age at presentation (HR: 0.93, 95% CI: 0.89–0.96;
P = 0.0001), 1-year bilirubin > ULN (HR: 5.64, 95% CI:
1.40–22.66; P = 0.01) and late histological stage (HR:
5.18, 95% CI: 2.19–12.25; P = 0.0001) were independent
associations. Excluding late histological stages, 1-year bil-
irubin >ULN (HR: 3.94, 95% CI: 1.09–14.13; P = 0.03)
remained as the only independent predictor of poor
outcome.
DISCUSSION
Our study is the ﬁrst to include an appropriate untreated
cohort, speciﬁcally concerned with evaluating 1-year bio-
chemical deﬁnitions as therapeutic surrogates in early
PBC. We found that 1-year biochemical features described
in UDCA response criteria occur spontaneously in 36.4%–
66.7% of early PBC patients; rates which are not far
different from those with UDCA in our own and pub-
lished series (Figure 1a). When excluding patients with
Table 3 | Biochemical characteristics in patients with early PBC (normal baseline bilirubin and albumin), at
presentation and after 1 year from study entry: (a) total cohort (n = 215), and (b) after exclusion of patients with late
histological stages (Scheuer’s III-IV) on baseline liver biopsy (n = 185). Values are given as median (range)
Reference
range
At
presentation
After 1
year P-value*
At
presentation
After 1
year P-value*
a) Untreated (n = 129) UDCA-treated (n = 86)
Total bilirubin
(lmol/L)
5–17 9 (3–16) 9 (2–133) 0.001 10 (5–17) 10 (5–21) 0.35
ALP (U/L) 42–128 240 (50–1730) 234 (59–990) 0.15 226.5 (42–1074) 180.5 (42–1220) 0.0001
AST (U/L) 5–40 44.5 (18–312) 45 (12–210) 0.90 58 (14–270) 45 (12–253) 0.0001
Albumin† (g/L) 35–50 42 (35–51) 42
(22-51)
0.15 42
(35-57)
42
(34-57)
0.78
b) Untreated (n = 107) UDCA-treated (n = 78)
Total bilirubin
(lmol/L)
8 (3–16) 9 (2–133) 0.009 9 (5–17) 10 (5–21) 0.22
ALP (U/L) 214 (50–1730) 210 (59–990) 0.05 225 (42–1074) 178 (42–1220) 0.0001
AST (U/L) 43 (18–201) 45 (12–210) 0.51 58 (18–180) 45 (12–177) 0.0001
Albumin‡ (g/L) 43 (35–51) 42 (22–51) 0.15 42 (35–57) 42 (34–57) 0.70
PBC, primary biliary cirrhosis; UDCA, ursodeoxycholic acid; ALP, alkaline phosphatase; AST, aspartate aminotransferase.
* P-values are based on Wilcoxon signed-rank test for paired data.
† Serum albumin concentrations at 1 year available in 170/215 (79.1%) patients.
‡ Serum albumin concentrations at 1 year available in 167/185 (90.3%) patients.
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late histology (known to adversely affect UDCA
response,26 and due to its imbalance between untreated
and UDCA groups), or considering those with less abnor-
mal baseline ALP or AST values, the attainment rates for
all four biochemical deﬁnitions were statistically compara-
ble between untreated and UDCA-treated patients (Fig-
ure 1b,c,d). Inconsistent performance of UDCA response
criteria in early PBC was previously shown in the Dutch
PBC study,16 where survival of nonresponders was compa-
rable to responders when the PA-I (P = 0.30), BA
(P = 0.96) and Rotterdam criteria (P = 0.43) were applied
to 225 histologically deﬁned early PBC patients. Similarly,
a recent evaluation of the reliability of BA, PA-I, TO and
Rotterdam deﬁnitions in early disease showed poor posi-
tive (0.3–1.7) and negative (0.8–3.6) likelihood ratios, and
therefore poor discrimination for either high- or low-risk
patients.18 In line with these older observations, and using
complication- and transplantation-free liver-related sur-
vival as an endpoint, we could not identify any signiﬁcant
associations (Figure 2a). However, our relatively small
sample of UDCA-treated patients (n = 86) may lack sufﬁ-
cient statistical power to detect signiﬁcance, as indicated
by a trend for better long-term outcomes in UDCA
responders. Importantly, even traditional prognostic
models such as the Mayo27 or Royal Free models20 are
not useful for early PBC, as most patients die from
Total cohort (n = 215)
Untreated (n = 129) UDCA-treated (n = 86)
After exclusion of late (Scheuer’s III/IV) baseline histological
stages (n = 185)
UDCA-treated, original series [Ref.]
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36.4
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51.2
40.3
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71.2
59.3
93.2
8689.883.7
64.4
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P = 0.16
P = 0.28P = 0.34
P = 0.09
74.1
56.6
81.5
67.9
88.988.7
63
41.5
P = 0.15
P = 0.29
P = 1.00
P = 0.98
UDCA: ursodeoxycholic acid; PBC: primary biliary cirrhosis; ALP: alkaline phosphatase; ULN: upper limit of
normal; AST: aspartate transaminase.
51.346.7
71.868.2
76.975.7
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P = 0.55
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P = 0.18
Patients with baseline AST≤2×ULN (n = 80)
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Figure 1 | Rates (%) of attainment of 1-year biochemical features fulﬁlling UDCA response deﬁnitions among 215
patients with early PBC (normal baseline bilirubin and albumin) untreated or UDCA-treated: (a) whole cohort
(n = 215); UDCA response rates in the original Barcelona, Paris-I, Toronto and Paris-II series are shown for
comparison, (b) excluding late histological stages (n = 185), (c) patients with baseline ALP ≤3x ULN (n = 145),
(d) patients with baseline AST ≤2x ULN (n = 80).
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Table 4 | Univariate and multivariate associations for attainment of 1-year biochemical features, as described in
Barcelona, Paris-I, Toronto and Paris-II deﬁnitions: (a) in a cohort of 215 PBC patients with normal baseline bilirubin
and albumin concentrations, and (b) after exclusion of patients with late (Scheuer’s III and IV) baseline histology
(n = 185)
Variable
Univariate
P-value Multivariate P-value
OR
(95% CI)
(a)
Barcelona
Age 0.64 – –
Gender 1.00 – –
UDCA treatment 0.03 0.03 2.16 (1.07–4.36)
Baseline ALP ≤3 9 ULN 0.0001 0.0001 4.80 (2.18–10.58)
Baseline AST ≤2 9 ULN 0.20 – –
Baseline histological stage: Scheuer’s I and II 0.001 0.02 3.87 (1.19–12.6)
High/Standard UDCA dose* 0.38 – –
Paris-I
Age 0.28 – –
Gender 0.17 – –
UDCA treatment 0.13 0.24 1.62 (0.72–3.63)
Baseline ALP≤3 9 ULN 0.0001 0.0001 9.95 (4.13–23.98)
Baseline AST≤2 9 ULN 0.0001 0.0001 9.34 (3.10–28.09)
Baseline histological stage: Scheuer’s I and II 0.0001 0.015 3.67 (1.23–9.1)
High/Standard UDCA dose* 0.43 – –
Toronto
Age 0.48 – –
Gender 0.50 – –
UDCA treatment 0.04 0.01 3.59 (1.35–9.53)
Baseline ALP ≤3 9 ULN 0.0001 0.0001 35.9 (13.71–94.30)
Baseline AST ≤2 9 ULN 0.10 – –
Baseline histological stage: Scheuer’s I and II 0.004 0.42 1.49 (0.42–5.29)
High/Standard UDCA dose* 0.33 – –
Paris-II
Age 0.51 – –
Gender 0.52 – –
UDCA treatment 0.13 0.02 2.84 (1.17–6.90)
Baseline ALP ≤3 9 ULN 0.0001 0.0001 34.23 (9.20–127.34)
Baseline AST ≤2 9 ULN 0.0001 0.0001 5.63 (2.23–14.22)
Baseline histological stage: Scheuer’s I and II 0.013 0.71 1.27 (0.36–4.49)
High/Standard UDCA dose* 0.23 – –
(b)
Barcelona
Age 0.63 – –
Gender 1.00 – –
UDCA treatment 0.18 0.05 1.92 (1.01–3.64)
Baseline ALP≤3 9 ULN 0.0001 0.0001 6.33 (2.86–13.98)
Baseline AST≤2 9 ULN 0.23 – –
High/Standard UDCA dose† 0.64 – –
Paris-I
Age 0.26 – –
Gender 0.22 – –
UDCA treatment 0.86 0.29 1.55 (0.69–3.49)
Baseline ALP≤3 9 ULN 0.0001 0.0001 7.97 (3.57–17.80)
Baseline AST≤2 9 ULN 0.0001 0.0001 5.71 (2.01–16.26)
High/Standard UDCA dose† 0.10 – –
Toronto
Age 0.44 – –
Gender 0.75 – –
1360 Aliment Pharmacol Ther 2013; 38: 1354-1364
ª 2013 The Authors. Alimentary Pharmacology & Therapeutics published by John Wiley & Sons Ltd
V. Papastergiou et al.
nonliver-related causes28 and only a minority have liver-
related deaths or LT. In a previous study,16 baseline biliru-
bin and albumin concentrations, both classic biochemical
predictors in PBC, were prognostically irrelevant in
early disease, highlighting difﬁculties for accurate prog-
nostication in this disease category. To our results,
baseline late histology, 1-year bilirubin >ULN and
inversely increasing age were the only independent
predictors of a poor outcome. A recent study also
found an inverse association with age with respect to
UDCA response and symptoms.27
PA-I are considered the best validated criteria, recom-
mended in clinical trials.29 In our early PBC cohort,
attainment of PA-I criteria was independent of UDCA
treatment, suggesting that the association between PA-I
criteria and prognosis is not driven by UDCA. Notably,
when patients with late histology were excluded, fulﬁl-
ment of TO criteria also occurred irrespective of UDCA
(however, there was a 1-year evaluation in our study vs.
evaluation for 2 years originally17). Congruent with our
ﬁndings that causal association of biochemical response
is suboptimal for UDCA, PA-I criteria were predictive of
long-term outcome in untreated patients with early PBC
(Figure 2b), conﬁrming data in abstract form.19
More recently, the PA-II criteria have been proposed
as the most reliable in early PBC,18 derived from 165
patients with early histology, using liver-related survival
or any clinical or histological evidence of development of
cirrhosis as endpoints.18 These criteria were also valid
for a nonhistological deﬁnition of early disease.18 We
evaluated both histological and nonhistological criteria
and found comparable results. Our patients with PA-II
response had a survival at 5, 10 and 15 years without an
adverse outcome of 100%, 96% and 96%, respectively ,
compared to 95% at all time-points originally pub-
lished,18 if early disease was deﬁned histologically. With
the nonhistological deﬁnition of early PBC, both the ori-
ginal cohort18 and our own had a 100% survival without
an adverse outcome. The same number of liver-related
deaths, LT or development of complications (n = 8)
occurred in both studies. However, although PA-II crite-
ria were speciﬁcally developed in early PBC, our data
clearly question the response criteria as adequately
reﬂecting the therapeutic beneﬁt of UDCA. This was
shown in multivariate analysis in which biochemical fea-
tures compatible with ‘treatment response’ were largely
related to baseline factors reﬂecting severity of the dis-
ease (ALP/AST levels and histological stage) and to a far
lesser extent, or not at all for some criteria, to UDCA
(Table 4). Notably, baseline ALP and AST were categor-
ised using thresholds of ≤3x ULN and ≤2x ULN, respec-
tively, as used in PA-I criteria14 (incorporating higher
ALP/AST thresholds), corresponding to patients with
baseline biochemistry likely to fulﬁl at least one response
criteria. Thus, if at baseline the thresholds for response
criteria are already present, then this confers a likelihood
to maintain them at 1 year irrespective of therapy. Nota-
bly, 37.7% of our cohort had a baseline ALP ≤1.5x ULN.
This subpopulation of early PBC patients diagnosed his-
tologically (poorly represented in previous studies evalu-
ating UDCA responses14, 15, 17, 18) has inﬂuenced our
results, as most maintain the criteria for 1 year irrespec-
Table 4 | (Continued)
Variable
Univariate
P-value Multivariate P-value
OR
(95% CI)
UDCA treatment 0.63 0.08 2.34 (0.91–6.03)
Baseline ALP≤3 9 ULN 0.0001 0.0001 38.01 (14.52–99.49)
Baseline AST≤2 9 ULN 0.03 0.67 1.22 (0.49–3.03)
High/Standard UDCA dose† 0.20 – –
Paris-II
Age 0.49 – –
Gender 0.50 – –
UDCA treatment 0.55 0.04 2.19 (1.03–4.70)
Baseline ALP≤3 9 ULN 0.0001 0.0001 31.89 (8.91–114.18)
Baseline AST≤2 9 ULN 0.0001 0.0001 3.92 (1.83–8.41)
High/Standard UDCA dose† 0.10 – –
PBC, primary biliary cirrhosis; UDCA, ursodeoxycholic acid; ALP, alkaline phosphatase; AST, aspartate transaminase; ULN, upper
normal limit; OR, odds ratio; CI, conﬁdence interval.
* 13–15 mg/kg/day; analysis regards 86 patients with UDCA treatment.
† 13–15 mg/kg/day; analysis regards 78 patients with UDCA treatment.
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Figure 2 | Kaplan–Meier plots of survival without adverse outcome (liver-related death, LT, complications) in patients
with early PBC (normal baseline bilirubin and albumin), according to 1-year biochemical criteria (Barcelona, Paris-I,
Paris-II and Toronto) attained: (a) after 1 year of UDCA therapy (n = 86), and (b) by natural biochemical variation in
patients with no treatment (n = 129). Dotted curves represent patients attaining criteria; solid curves represent
patients not attaining the criteria. LT, liver transplantation; PBC, primary biliary cirrhosis; UDCA, ursodeoxycholic acid.
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tive of receiving any treatment. However, spontaneous
biochemical improvement also occurred, fulﬁlling UDCA
response criteria in untreated patients with more pro-
nounced baseline biochemical abnormalities (ALP ≤3x
ULN or AST ≤2x ULN) in whom attainment rates for
some criteria exceeded 80% (Figure 1c,d). Critically, our
data suggest that the therapeutic beneﬁt with UDCA
may have been overestimated in early PBC. This may
provide an explanation as to why almost 2/3 of PBC
patients achieve responses with UDCA, but only approx-
imately 25% achieve 15-year survival without an adverse
outcome, including histological progression to late
stages.14, 18 Given the slowly evolving character of the
disease, longer evaluation periods (2–3 years, or more)
may be necessary for a thorough assessment of UDCA
response in early PBC. However, such subanalysis was
not feasible with our data, as serial biochemical testing
at time-points later than 1 year from UDCA start was
not available. With current criteria, the optimal timing
for UDCA response assessment in early PBC remains to
be addressed in future studies.
Our study has limitations mainly concerning ‘subop-
timal’ UDCA dosing in some patients, although we
could not detect any statistically signiﬁcant effect in
either biochemical or clinical endpoints. Secondly, we
observed only a 20% reduction in median ALP con-
centration, whereas it was 50% in the PA-II study.18
However, our median baseline ALP levels were
226.5 U/L (only 1.8x ULN) vs. a mean of 3.6x ULN
for PA-II cohort,18 precluding a more pronounced
UDCA-induced reduction in ALP serum concentrations
in our population, because of lower baseline values.
Despite this, our overall UDCA response rates are not
markedly different from those in the original cohorts,
i.e. 61% for both BA and PA-I criteria,14, 15 56.5% for
TO17 and 53% for PA-II18 (Figure 1a). The higher rate
of PA-I response (76.7% vs. 61% originally14) is proba-
bly accounted by fewer patients with late histology
(18.5% vs. 45%). Contrarily, our late histology rate is
comparable to that in TO (21.7%) and BA (23.7%)
series, even though neither study was speciﬁcally con-
cerned with early disease.
In conclusion, our data show that current criteria for
assessing response to UDCA are not robust enough for
use in early PBC. Biochemical responses at 1 year give a
good measure of disease severity, and thus may represent
a reliable predictor of long-term prognosis, but provide
little or no information on response to UDCA. Our ﬁnd-
ings demonstrate the need to further reﬁne biochemical
response criteria to establish a reliable causal link
between outcomes and treatment effects. This will allow
accurate patient selection for future clinical trials, helping
efforts for developing new therapeutic approaches in
PBC.
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